Literature DB >> 22797869

C (max) and t (max) verification using Fibonacci sequence and absorption rate.

Tomasz Grabowski1, Jerzy J Jaroszewski, Beata Borucka, Hubert Ziółkowski.   

Abstract

The aim of this study was to verify the values of maximal observed concentration (C max,obs) and the time, at which maximum concentration is observed (t max,obs) using the analysis of the absorption rate constant (k ab). It focused on the changes in concentration over time (C-T) for drugs, for which several peaks of concentration occur. In addition, the attempt was made to use Fibonacci sequence to facilitate the visual analysis of the dynamics in changes of concentration on C-T graphs. The analyses were conducted with the use of three hypothetical data groups (groups I, II and III), which had distinct C-T profiles, and with the in vivo data form healthy subjects (n = 10) taking part in a bioequivalence study, who was given a single oral dose of topiramate (100 mg). The comparison of hypothetical and real in vivo data demonstrated that for the C-T curves, in which there are several peaks of concentration C max,obs and t max,obs values can easily be miscalculated when the increase in concentration is not properly related to the appropriate absorption phase (63.2, 87.50, 96.88 %). It was also demonstrated that the data transformation with the use of Fibonacci sequence exposes slight differences in the observed concentration values in a semi-logarithmic scale. The results of this study show that in case of C-T curves with several peaks of concentration, the verification of C max and t max data obtained taking into account different absorption phases enables more precise evaluation of these parameters.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22797869     DOI: 10.1007/s13318-012-0101-1

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  24 in total

1.  First measured plasma concentration value as C(max); impact on the C(max) confidence interval in bioequivalence studies.

Authors:  A Jackson; D Conner; R Miller
Journal:  Biopharm Drug Dispos       Date:  2000-05       Impact factor: 1.627

Review 2.  Noncompartmentally-based pharmacokinetic modeling.

Authors:  P Veng-Pedersen
Journal:  Adv Drug Deliv Rev       Date:  2001-06-11       Impact factor: 15.470

3.  A systematic methodology review of phase I radiation dose escalation trials.

Authors:  Madelon Pijls-Johannesma; Ghislaine van Mastrigt; Steve M Hahn; Dirk De Ruysscher; Brigitta G Baumert; Guido Lammering; Jeroen Buijsen; Soren M Bentzen; Yolande Lievens; Andrew Kramar; Philippe Lambin
Journal:  Radiother Oncol       Date:  2010-03-24       Impact factor: 6.280

4.  Tmax: an unconfounded metric for rate of absorption in single dose bioequivalence studies.

Authors:  R P Basson; B J Cerimele; K A DeSante; D C Howey
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

5.  Pharmacokinetic evaluation of a sprinkle-dose regimen of a once-daily, extended-release morphine formulation.

Authors:  Lise Eliot; Jackie Butler; John Devane; Gordon Loewen
Journal:  Clin Ther       Date:  2002-02       Impact factor: 3.393

6.  A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption.

Authors:  Y Plusquellec; G Campistron; S Staveris; J Barre; L Jung; J P Tillement; G Houin
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

7.  Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.

Authors:  Peter Jenner; Michael Könen-Bergmann; Cornelia Schepers; Sebastian Haertter
Journal:  Clin Ther       Date:  2009-11       Impact factor: 3.393

8.  Effect of obesity and major weight reduction on gastric emptying.

Authors:  C Verdich; J L Madsen; S Toubro; B Buemann; J J Holst; A Astrup
Journal:  Int J Obes Relat Metab Disord       Date:  2000-07

9.  A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin.

Authors:  Michael H Davidson; Peter Lukacsko; Jim X Sun; Gale Phillips; Edward Walters; Arnold Sterman; Robert Niecestro; Lawrence Friedhoff
Journal:  Clin Ther       Date:  2002-01       Impact factor: 3.393

10.  Mechanistic understanding of time-dependent oral absorption based on gastric motor activity in humans.

Authors:  Kazutaka Higaki; Sally Y Choe; Raimar Löbenberg; Lynda S Welage; Gordon L Amidon
Journal:  Eur J Pharm Biopharm       Date:  2008-03-07       Impact factor: 5.571

View more
  3 in total

1.  Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort.

Authors:  Jeffry Adiwidjaja; Alan V Boddy; Andrew J McLachlan
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

2.  Food-Drug Interaction between the Adlay Bran Oil and Drugs in Rats.

Authors:  Hsien-Tsung Yao; Jia-Hsuan Lin; Yun-Ta Liu; Mei-Ling Li; Wenchang Chiang
Journal:  Nutrients       Date:  2019-10-15       Impact factor: 5.717

3.  Beverage-Drug Interaction: Effects of Green Tea Beverage Consumption on Atorvastatin Metabolism and Membrane Transporters in the Small Intestine and Liver of Rats.

Authors:  Hsien-Tsung Yao; Ya-Ru Hsu; Mei-Ling Li
Journal:  Membranes (Basel)       Date:  2020-09-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.